Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993835 | 1.00 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2415851 | 1.00 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2916532 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Acrylamide SCHEMBL28298600 | 0.87 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7377152 | 0.85 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL16856366 | 0.82 | — | — | |
| SCHEMBL2915344 | 0.82 | PRCP (0.39) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL5892835 | 0.81 | HDAC8 (0.32) | CHRNB2CHRNA4CHRNA7PRCP | |
| SCHEMBL19996549 | 0.80 | PRCP (0.45) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL3652033 | 0.80 | L3MBTL1 (0.50) | CHRNB2CHRNA4CHRNA7L3MBTL1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399681-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | BIGNAN GILLES (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2513096-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-A MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-8263781-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| WO-2011075565-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | CHRNB2 3434/4885CHRNA4 3641/4885CHRNA7 3904/4885 |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | CHRNB2 3434/4885CHRNA4 3641/4885CHRNA7 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.